MAP3K13抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain using P06856(KNG1 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The MAP3K13 antibody is a crucial tool for studying the mitogen-activated protein kinase kinase kinase 13 (MAP3K13), also known as LZK (leucine zipper-bearing kinase). MAP3K13 is a serine/threonine kinase within the MAP3K family, playing a role in regulating stress-activated signaling pathways, including the JNK (c-Jun N-terminal kinase) and p38 MAPK cascades. These pathways are involved in cellular responses to inflammation, apoptosis, differentiation, and survival. MAP3K13 is expressed in various tissues, particularly the brain, and has been implicated in neurodegenerative diseases, cancer, and metabolic disorders. For instance, it regulates neuronal survival and axon degeneration, while its dysregulation is linked to tumor progression in certain cancers.

The antibody specifically detects endogenous MAP3K13 protein, enabling researchers to analyze its expression, localization, and activation status in different biological contexts. It is widely used in techniques like Western blotting (WB), immunohistochemistry (IHC), and immunofluorescence (IF). Validated antibodies ensure specificity through knockdown/knockout controls, confirming minimal cross-reactivity with related kinases like MAP3K12. Commercial MAP3K13 antibodies are available from suppliers such as Cell Signaling Technology, Abcam, and Santa Cruz Biotechnology, often with detailed protocols for experimental optimization. Ongoing research focuses on its therapeutic potential, particularly in targeting MAP3K13-driven pathways in cancer or neurodegeneration, making reliable antibodies essential for mechanistic studies and drug development.